In addition, inhibitors of JAK2 and STAT3 can dampen calprotectin production, and we have demonstrated the efficacy of JAK2 inhibitors Fedratinib and Momelotinib in blocking S100a8 release in human neutrophils, thus providing a rationale for the repurposing of these clinically approved drugs for severe COVID-19. The gene discussed is S100A8; the disease is COVID-19.